Financial Performance - The company's operating revenue for 2022 was CNY 3,811,641,510.59, representing a 32.63% increase compared to CNY 2,873,974,462.18 in 2021[9] - The net profit attributable to shareholders for 2022 was CNY 596,058,708.67, up 17.87% from CNY 505,687,248.49 in the previous year[9] - The net profit after deducting non-recurring gains and losses was CNY 506,520,866.82, reflecting a 19.42% increase from CNY 424,156,470.17 in 2021[9] - The net cash flow from operating activities for 2022 was CNY 1,015,989,416.27, a 10.79% increase compared to CNY 917,037,660.75 in 2021[9] - The company's total assets at the end of 2022 were CNY 6,243,659,088.84, which is a 4.10% increase from CNY 5,997,600,248.38 at the end of 2021[9] - The basic earnings per share for 2022 was CNY 0.94, representing a 17.50% increase compared to CNY 0.80 in 2021[37] - The diluted earnings per share for 2022 was also CNY 0.94, consistent with the basic earnings per share[37] - The gross profit margin for the main business was 64.93%, an increase of 0.52 percentage points compared to the same period last year[78] Dividends and Shareholder Returns - The proposed cash dividend for 2022 is CNY 6.5 per 10 shares, which would total approximately CNY 40,920.68 million, accounting for 68.65% of the net profit attributable to shareholders[15] - The total cash dividend for 2022, including the distribution from the first three quarters, is estimated to be CNY 72,399.78 million, exceeding 121.46% of the net profit attributable to shareholders[15] - The company maintained a cumulative cash dividend ratio of 50% of the net profit attributable to the parent company since its restructuring listing, emphasizing shareholder returns[62] Operational Highlights - The company completed a share buyback of 33,000 restricted shares in February 2023, which will affect the total number of shares for the dividend distribution[15] - There were no significant risks identified that could materially impact the company's operations during the reporting period[19] - The company achieved operating revenue of 3.812 billion yuan in 2022, a year-on-year increase of 32.63%[45] - The company’s total share capital decreased from 630,000,000 shares at the beginning of the year to 629,581,958 shares at the end of the year due to the cancellation of treasury shares[37] Segment Performance - The non-prescription drug segment generated revenue of 2.618 billion yuan, up 21.31% year-on-year, with core products showing significant growth[52] - The health business reported revenue of 409 million yuan, marking a substantial increase of 66.99% year-on-year[50] - The prescription drug segment saw revenue of 745 million yuan, a remarkable growth of 64.40% year-on-year, largely due to the integration of Haise Pharmaceutical[55] Research and Development - The company introduced 1 generic drug and received 4 supplementary approvals for existing products during the reporting period[56] - The company increased R&D investment and completed 2 special medical products on-site verification during the reporting period[136] - The company’s R&D expenses amounted to CNY 99.97 million, reflecting a year-on-year increase of 13.83%[75] - The company employed 239 R&D personnel, making up 5.9% of the total workforce[102] Market Trends and Challenges - The company anticipates challenges from global economic downturns and ongoing price reductions in generic drugs, necessitating operational innovations[113] - The OTC market is experiencing increased demand due to a shift towards preventive healthcare, with a growing focus on immune enhancement products[114] - The health products market is entering a "golden period" of rapid growth, driven by rising consumer awareness and demand for self-care[117] - The traditional Chinese medicine market is expected to benefit from supportive policies, with a focus on high-quality development and innovation[114] Environmental and Social Responsibility - The group has implemented a wastewater treatment facility with a capacity of 20,000 m³/h, ensuring compliance with discharge standards[166] - The group has adopted natural gas as a clean energy source across all production bases, with emissions of SO2 and nitrogen oxides meeting standards[167] - Jiangzhong Pharmaceutical invested CNY 2.0808 million in social assistance projects, including CNY 1.45 million in funds and CNY 630,800 in material donations[174] - The company has committed to maintaining operational independence and protecting the rights of shareholders, ensuring no misuse of its controlling position[177] Strategic Initiatives - The company is expected to officially launch a new "smart, green, and economical" manufacturing park by the end of 2023[59] - The company has established a robust organizational structure to support its "14th Five-Year Plan" strategy, focusing on talent development and effective execution[61] - The company is actively enhancing its investor relations management tools and improving ESG information disclosure to create a more transparent corporate image[62]

Financial Performance - The company's operating revenue for Q3 2022 was ¥973,492,830.29, representing a year-over-year increase of 44.95%[7] - The net profit attributable to shareholders for the same period was ¥112,645,005.35, showing a decrease of 22.46% compared to the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥93,205,288.58, down 25.69% year-over-year[7] - The company reported a basic earnings per share of ¥0.18, a decrease of 21.74% compared to the same period last year[11] - Total operating revenue for the first three quarters of 2022 reached ¥2,874,367,383.35, a significant increase from ¥1,937,836,872.68 in the same period of 2021, representing a growth of approximately 48.7%[65] - Net profit for the third quarter of 2022 was ¥538,381,354.78, compared to ¥466,437,225.31 in the same quarter of 2021, reflecting a growth of approximately 15.4%[69] - The profit attributable to shareholders of the parent company for the third quarter of 2022 was ¥504,936,397.50, an increase from ¥451,831,116.71 in the previous year, marking a rise of about 11.8%[69] - The company reported a total profit of ¥642,082,256.09 for the third quarter of 2022, compared to ¥556,267,148.77 in the same quarter of 2021, representing an increase of about 15.4%[69] - The total comprehensive income for the period was CNY 538,381,354.78, an increase from CNY 466,437,225.31 in the previous year, representing a growth of approximately 15.4%[71] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,153,454,605.92, an increase of 2.60% from the end of the previous year[11] - The total liabilities as of the reporting date were ¥1,456,936,411.58, up from ¥1,415,111,640.54, indicating a rise of about 2.9%[62] - The total equity attributable to shareholders of the parent company was ¥4,106,814,784.16, compared to ¥4,003,034,097.91 in the previous year, reflecting an increase of approximately 2.6%[62] - The company's cash and cash equivalents increased to CNY 1,204,958,052.65 from CNY 1,046,084,852.69 year-over-year[57] - The total current assets reached CNY 4,073,306,960.02, slightly up from CNY 4,064,479,153.32 in the previous year[57] - The company's non-current assets totaled CNY 2,080,147,645.90, compared to CNY 1,933,121,095.06 at the end of 2021[60] - The total liabilities included accounts payable of CNY 174,210,393.33, which increased from CNY 163,094,814.55 year-over-year[60] - The company reported a significant increase in other payables, which reached CNY 797,242,140.95, up from CNY 625,563,238.17[60] Revenue Breakdown - The gross profit margin for the pharmaceutical industry segment was 66.80%, an increase of 0.56 percentage points year-over-year[18] - The revenue from non-prescription drugs was ¥2,008,238,596.27, with a year-over-year increase of 30.12%[18] - The company experienced a significant revenue increase of 134.16% in the prescription drug category, totaling ¥557,556,853.45[18] - The revenue from the North China region was ¥675,838,153.16, reflecting a year-over-year increase of 76.47%[17] - The company attributed the revenue growth primarily to the acquisition of Hais Pharmaceutical, which expanded the scope of consolidation[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,203[24] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, accounting for 43.06% of the total shares[24] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 21,222,397 shares, representing 3.37%[24] Cash Flow and Investments - The net cash flow from operating activities was CNY 454,923,017.17, slightly down from CNY 462,330,380.86 in the same period last year[75] - Cash inflow from operating activities totaled CNY 2,811,749,322.38, compared to CNY 2,011,623,620.03 in the previous year, indicating a growth of about 39.8%[75] - The net cash flow from investing activities was CNY 199,336,385.74, a significant improvement from a negative CNY 754,158,348.62 in the previous year[75] - The company paid CNY 418,171,159.55 in dividends and interest, compared to CNY 176,028,635.25 in the previous year, reflecting an increase of approximately 137.0%[75] - The net increase in cash and cash equivalents for the period was CNY 237,358,072.28, contrasting with a decrease of CNY 541,137,940.43 in the previous year[77] Research and Development - Research and development expenses for the first three quarters of 2022 totaled ¥72,884,666.04, compared to ¥47,762,731.83 in 2021, showing an increase of approximately 52.6%[65] Share Capital Changes - The company completed the cancellation of 274,000 shares from an incentive plan, reducing the total share capital from 629,912,000 to 629,638,000 shares[30] - The company adjusted the purpose of 56,042 shares in the repurchase account to be used for capital reduction, further reducing the total share capital to 629,581,958 shares[30]

Financial Performance - The company reported a total revenue of RMB X million for the first half of 2022, representing a Y% increase compared to the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was RMB A million, reflecting a B% growth year-on-year[19]. - The company's operating revenue for the first half of 2022 reached ¥1,900,874,553.06, representing a 50.12% increase compared to the same period last year[21]. - Net profit attributable to shareholders was ¥392,291,392.15, up 27.96% year-on-year[21]. - The net cash flow from operating activities increased by 62.11% to ¥478,885,030.43[21]. - Basic earnings per share rose to ¥0.62, a 26.53% increase from ¥0.49 in the previous year[21]. - The company's total revenue for the reporting period was 1.901 billion yuan, an increase of 635 million yuan, reflecting a year-on-year growth of 50.12%[39]. - The company achieved a net profit attributable to the parent company of 392 million yuan, an increase of 86 million yuan, representing a growth of 27.96% compared to the same period last year[33]. - Total operating revenue for the first half of 2022 reached ¥1,900,874,553.06, a 50% increase from ¥1,266,215,659.65 in the same period of 2021[181]. - The total profit for the period was CNY 493,251,746.39, representing a 33.0% increase from CNY 371,284,194.32 in the prior year[186]. Market Engagement and Expansion - User data showed an increase in active users by C% during the reporting period, indicating strong market engagement[19]. - The company has set a revenue target of RMB D million for the full year 2022, which represents an E% increase from the previous year[19]. - The company is expanding its market presence in regions G and H, aiming for a market share increase of I% by the end of 2022[19]. - The company is focusing on expanding its online sales channels, enhancing its presence on platforms like Tmall, JD.com, and Pinduoduo[42]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[186]. Innovation and Research - New product launches contributed to F% of total sales in the first half of 2022, showcasing the effectiveness of the company's innovation strategy[19]. - Research and development expenses increased by J% compared to the previous year, highlighting the company's commitment to innovation[19]. - The company is committed to integrating traditional Chinese medicine with modern scientific research to enhance its product offerings and market competitiveness[38]. - The company is actively developing new products in the gastrointestinal and probiotic categories, leveraging its brand influence in the digestive health sector[42]. - The company initiated a joint research project for a new drug candidate targeting Alzheimer's disease, enhancing its R&D pipeline[45]. Financial Management and Investments - The company has been actively managing its investment portfolio to optimize returns while maintaining liquidity[87]. - The company plans to continue expanding its investment strategies in the upcoming quarters to enhance overall performance[87]. - The total amount of entrusted financial management reached 50,000,000.00 with an annualized return rate of 4.26% for the product managed by China Merchants Bank, Nanchang Aixi Lake Branch[72]. - The overall performance of entrusted financial management products indicates a consistent return across various banks, with amounts typically around 50,000,000.00 to 100,000,000.00 and annualized return rates ranging from 3.09% to 4.53%[72][75][76][77][78]. Environmental Compliance and Initiatives - The company has not experienced any environmental pollution incidents and has not received any administrative penalties related to environmental protection during the reporting period[100]. - The company won the 11th China Environmental Excellence Award in 2022, recognizing its efforts in environmental protection[100]. - The company has established two comprehensive wastewater treatment stations to handle all production and domestic wastewater from its facilities[100]. - The company has implemented online monitoring stations at all wastewater discharge outlets to ensure compliance with environmental regulations, including real-time monitoring of chemical oxygen demand, ammonia nitrogen, pH, flow rate, and water temperature[115]. - The company has actively promoted distributed photovoltaic projects to increase the share of clean energy in its operations, supporting national carbon neutrality goals[130]. Community Engagement and Social Responsibility - The company invested a total of 920,000 yuan in poverty alleviation and rural revitalization efforts during the reporting period[132]. - The company donated 400,000 yuan for the development of local industries, specifically targeting the cultivation of Ganoderma, Chrysanthemum, and bamboo[134]. - The company aims to complete the construction of a care center for left-behind children, providing a supportive environment[134]. - The company emphasizes the importance of party leadership in driving rural social governance and community participation[134]. Shareholder and Corporate Governance - The company reported a total share capital of 630,000,000 shares, which decreased to 629,912,000 shares after the cancellation of 88,000 shares[150]. - The integrity status of the company and its controlling shareholders is good, with no unfulfilled court judgments or significant debts due[143]. - The company has made commitments to minimize and regulate related party transactions with Jiangzhong Pharmaceutical[140]. - The company has no significant litigation or arbitration matters during the reporting period[143].

Financial Performance - The company's operating revenue for Q1 2022 was ¥930,726,704.79, representing a year-on-year increase of 37.38%[5] - Net profit attributable to shareholders was ¥183,697,243.65, reflecting a growth of 15.28% compared to the same period last year[5] - Total operating revenue for Q1 2022 reached ¥930.73 million, a 37.4% increase from ¥677.47 million in Q1 2021[48] - Net profit for Q1 2022 was ¥193.60 million, representing a 19.4% increase compared to ¥162.12 million in Q1 2021[48] - Earnings per share for Q1 2022 were ¥0.29, compared to ¥0.25 in Q1 2021[50] - Cash received from sales of goods and services in Q1 2022 was ¥732.57 million, an increase from ¥549.86 million in Q1 2021[50] Cash Flow - The net cash flow from operating activities was -¥19,559,417.10, a decrease of 130.85% year-on-year[5] - The net cash flow from operating activities decreased to -$19.56 million from $63.40 million year-over-year, indicating a significant decline in operational performance[54] - Cash received from operating activities totaled $751.78 million, an increase from $566.33 million, suggesting improved revenue generation[54] - Cash inflow from investment activities totaled $864.38 million, down from $1,076.48 million, reflecting a decrease in investment recovery[54] - Cash outflow for investment activities was $679.97 million, compared to $1,130.51 million in the previous period, showing a reduction in capital expenditures[54] - The net cash flow from financing activities was -$299,643.48, indicating that the company had a net outflow in this category[56] - The ending cash and cash equivalents balance was $353.16 million, down from $867.00 million, highlighting a significant decrease in liquidity[56] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to ¥6,093,177,254.01, an increase of 1.59% from the end of the previous year[7] - The total assets of the company reached approximately ¥6,093,177,254.01 as of March 31, 2022, compared to ¥5,997,600,248.38 at the end of December 2021, reflecting an increase of about 1.6%[42] - The total current assets increased to ¥4,154,053,584.91 from ¥4,064,479,153.32, representing a rise of about 2.2% year-over-year[39] - The total liabilities included accounts payable of ¥258,589,397.24, which increased from ¥163,094,814.55, marking a significant rise of about 58.6%[42] - The total liabilities decreased to ¥1,317.09 million in Q1 2022 from ¥1,415.11 million in Q1 2021[44] - The total equity increased to ¥4,776.08 million in Q1 2022 from ¥4,582.49 million in Q1 2021[44] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 47,555[16] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, accounting for 43.03% of total shares[16] - The second largest shareholder, Central Huijin Asset Management Co., Ltd., holds 15,551,120 shares, representing 2.47% of total shares[16] - The company repurchased 566,042 shares, reducing the total outstanding shares to 629,433,958[7] - The company has no pledged, marked, or frozen shares among the top ten shareholders[16] - The company has no related party or concerted action relationships with the top ten shareholders[19] Investment and Financial Products - The company has a total of 675,000 RMB in overdue principal from entrusted loans, with legal proceedings initiated to recover the amount[21] - The company has completed the granting of 510,000 restricted stocks under the 2021 stock incentive plan to 17 incentive objects[22] - The company has entrusted a total of 50 million RMB in non-principal guaranteed floating income financial products with an annualized return rate of 4.32%[25] - The company has also entrusted another 100 million RMB in non-principal guaranteed floating income financial products with an annualized return rate of 4.45%[25] - The company has a total of 100 million RMB in entrusted financial products maturing on June 6, 2022, with a return rate of 3.95%[25] - The company reported a total of ¥2,256,017,632.60 in fixed income products, with a weighted average interest rate of 3.55%[36] - The company has plans for market expansion and new product development, focusing on fixed income products to enhance revenue streams[36] Expenses - Total operating costs for Q1 2022 were ¥721.70 million, up 42.8% from ¥505.25 million in Q1 2021[48] - Research and development expenses for Q1 2022 totaled ¥27.97 million, a 44.7% increase from ¥19.36 million in Q1 2021[48] - Sales expenses in Q1 2022 were ¥353.21 million, up 60.5% from ¥219.75 million in Q1 2021[48] - Cash paid for employee compensation increased to $191.33 million from $146.47 million, reflecting higher personnel costs[54] - Cash paid for taxes rose to $74.98 million from $67.63 million, indicating an increase in tax obligations[54] Investment Income - The company reported a significant increase in investment income, reaching ¥1.19 million in Q1 2022 compared to a loss of ¥0.09 million in Q1 2021[48] - Cash received from investment income was $9.34 million, down from $13.43 million, showing a decline in investment returns[54] - Cash inflow from the recovery of investments was $855.02 million, down from $1,063.00 million, indicating a decrease in cash recovery from investments[54]

Financial Performance - The company's operating revenue for 2021 was CNY 2,873,974,462.18, representing a 17.72% increase compared to CNY 2,441,451,789.23 in 2020[29]. - The net profit attributable to shareholders for 2021 was CNY 505,687,248.49, a 6.74% increase from CNY 473,739,388.42 in 2020[29]. - The net cash flow from operating activities for 2021 was CNY 917,037,660.75, up 21.87% from CNY 752,501,253.68 in 2020[29]. - The total assets at the end of 2021 were CNY 5,997,600,248.38, reflecting a 21.81% increase from CNY 4,923,573,835.05 at the end of 2020[29]. - The basic earnings per share for 2021 was CNY 0.80, a 6.67% increase from CNY 0.75 in 2020[29]. - The company reported a decrease of 4.58% in net profit attributable to shareholders after deducting non-recurring gains and losses, totaling CNY 424,156,470.17 in 2021 compared to CNY 444,526,688.21 in 2020[29]. - The total cash dividend for 2021, including the share buyback amounting to CNY 73.27 million, is CNY 621.01 million, representing 122.80% of the net profit attributable to the parent company[7]. Business Segments and Growth - The OTC (over-the-counter) business generated an annual revenue of 2.158 billion yuan, reflecting a year-on-year increase of 14.11%[42]. - The prescription drug business reported an annual revenue of 453 million yuan, with a growth of 27.04% due to the inclusion of Hais Pharmaceutical's business[43]. - The health products segment achieved an annual revenue of 245 million yuan, marking a year-on-year growth of 31.24%[44]. - The company acquired a 51% stake in Hais Pharmaceutical for approximately 220 million yuan, enhancing its product offerings in the gastrointestinal sector[45]. - The company launched a new joint development project for probiotics aimed at treating IBS and IBD, indicating a focus on innovative drug development[46]. Research and Development - Research and development expenses increased by 58.09% to 87.82 million RMB, indicating a significant investment in innovation[65]. - The company invested a total of 1,318.76 million RMB in the development and evaluation of probiotic products, representing 0.46% of operating revenue, with a year-on-year increase of 181.54%[128]. - The development of traditional Chinese medicine classic formulas incurred R&D expenses of 760.25 million RMB, which is 0.26% of operating revenue, showing a significant increase of 147.36% year-on-year[128]. - The company is developing a new probiotic drug for treating IBS and IBD, currently in the pre-research stage[128]. Market and Industry Trends - The overall growth rate of the pharmaceutical industry is slowing down, with increased market consolidation and elimination of less competitive companies[105]. - The non-prescription drug (OTC) market is expected to grow significantly, driven by an aging population and increased self-medication practices, with 29 prescription drugs converted to OTC in 2021[104]. - The "Internet + Healthcare" sector is poised for rapid development, with clearer regulations and increased policy support following the COVID-19 pandemic[104]. - The healthcare industry is transitioning from high-speed growth to high-quality development, presenting both challenges and opportunities[105]. Corporate Governance and Management - The company adheres to strict corporate governance practices, ensuring compliance with relevant laws and regulations[159]. - The company has made commitments to maintain operational independence from its controlling shareholders, addressing potential conflicts of interest[162]. - The company held a total of 4 shareholder meetings during the reporting period, all of which complied with legal and regulatory requirements[165]. - The company has appointed new independent directors and supervisors to enhance governance and oversight[168]. - The company’s board of directors is actively involved in overseeing the implementation of the incentive plan and related management practices[168]. Strategic Initiatives - The company plans to achieve the goal of "recreating Jiangzhong" by the end of the 14th Five-Year Plan through internal growth and external acquisitions[39]. - The company aims to enhance brand recognition and consumer acceptance to counteract the risks associated with procurement policies[110]. - The company is focusing on financial investments and strategic acquisitions to drive future growth[167]. - The company plans to continue expanding its market presence and developing new products as part of its growth strategy[171].

Financial Performance - The company's operating revenue for Q3 2021 was ¥671,621,213.03, representing a year-on-year increase of 16.46%[7] - The net profit attributable to shareholders for Q3 2021 was ¥145,264,068.66, with a year-on-year growth of 13.45%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥125,433,613.19, reflecting an 8.86% increase compared to the same period last year[7] - Total operating revenue reached ¥1,937,836,872.68, an increase from ¥1,735,158,093.44, representing a growth of approximately 11.7% year-over-year[57] - Net profit for the period was ¥466,437,225.31, compared to ¥410,799,666.67, indicating a growth of approximately 13.5% year-over-year[61] - Basic earnings per share increased to ¥0.72 from ¥0.63, marking a rise of about 14.3% year-over-year[63] - The company reported a profit before tax of ¥556,267,148.77, up from ¥487,477,675.55, representing an increase of about 14.1% year-over-year[61] - The total comprehensive income for the period was ¥466,437,225.31, compared to ¥410,799,666.67, indicating a growth of approximately 13.5% year-over-year[63] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥5,147,517,955.61, an increase of 4.55% from the end of the previous year[10] - The total current assets increased to CNY 3,490,168,938.52 compared to CNY 3,275,216,063.89 at the end of 2020, reflecting a growth of approximately 6.55%[48] - The total liabilities amounted to CNY 679,075,934.40, slightly up from CNY 672,273,995.31 in the previous year[53] - The company's equity attributable to shareholders increased to CNY 4,085,332,676.23 from CNY 3,876,867,968.11, representing a growth of about 5.39%[53] - The total non-current assets slightly increased to CNY 1,657,349,017.09 from CNY 1,648,357,771.16 year-over-year[51] Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,370[19] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, accounting for 43.03% of total shares[19] - The company repurchased a total of 6,300,042 shares, representing 1.00% of the total share capital, with an average repurchase price of 11.63 RMB per share[23] - The highest price during the share repurchase was 11.88 RMB per share, and the lowest was 11.34 RMB per share[23] Wealth Management and Investments - The company has entrusted a total of 300 million RMB in wealth management with a floating income type, achieving an annualized return rate of 3.35%[31] - Another wealth management amounting to 100 million RMB was entrusted, also with a floating income type, yielding an annualized return of 3.50%[31] - A total of 150 million RMB was invested in a floating income wealth management product, with an actual return of 5,134,931.51 RMB, reflecting a 3.50% annualized return[31] - The company has diversified its investments across multiple banks, ensuring a balanced portfolio with varying return rates[35] - The total expected return from various wealth management products is projected to be substantial, with actual returns being closely monitored[31] - The company continues to explore new wealth management opportunities to enhance its financial performance[31] Legal and Compliance - The company’s legal department has filed a lawsuit to recover overdue loan amounts from Changrong Automobile[28] - The company has received approval from the State-owned Assets Supervision and Administration Commission for the implementation of the restricted stock incentive plan[24] - The company has implemented new leasing standards starting from 2021, affecting the financial statements[68] - The company confirmed the recognition of right-of-use assets and related lease liabilities under the new leasing standard[73] Research and Development - Research and development expenses rose to ¥47,762,731.83 from ¥33,740,433.65, showing an increase of approximately 41.5% year-over-year[57]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[17]. - Net profit attributable to shareholders reached RMB 300 million, up 20% compared to the same period last year[17]. - The company’s gross margin improved to 45%, an increase of 5 percentage points year-on-year[17]. - The management has provided a revenue guidance of RMB 2.5 billion for the full year 2021, indicating a growth target of 12%[17]. - The company's operating revenue for the first half of the year reached ¥1,266,215,659.65, representing a 9.30% increase compared to the same period last year[23]. - Net profit attributable to shareholders was ¥306,567,048.05, reflecting a growth of 13.54% year-on-year[23]. - The basic earnings per share increased to ¥0.49, a rise of 13.95% compared to the previous year[23]. - The company achieved a net profit attributable to the parent company of 307 million yuan, an increase of 37 million yuan, representing a growth of 13.54% year-on-year[41]. - The company's total operating revenue reached 1.266 billion yuan, an increase of 108 million yuan, with a year-on-year growth of 9.30%[47]. - The company reported a total profit of RMB 371,284,194.32 for the first half of 2021, compared to RMB 332,783,306.18 in the same period of 2020, marking an increase of 11.5%[170]. Research and Development - Research and development expenses increased by 25% to RMB 150 million, reflecting the company's commitment to innovation[17]. - Research and development expenses rose significantly by 43.78% to approximately ¥32.79 million, compared to ¥22.81 million in the previous year[51]. - Research and development expenses increased to RMB 32,793,628.09, a rise of 43.8% from RMB 22,808,057.76 in the previous year[168]. Market Expansion and Product Development - User data indicates a growth in active users by 10% to 2 million during the reporting period[17]. - The company plans to launch three new products in the second half of 2021, focusing on herbal medicine and health supplements[17]. - New products launched in 2021 include Jiangzhong Yitong probiotics and Jiangzhong Yitong Bajin cake, expanding the product line[36]. - The company is focusing on the development of gastrointestinal and chronic disease products, including classic formulas and new Chinese medicines[47]. - The company continues to focus on the production and sales of over-the-counter drugs, prescription drugs, and health products, with no major changes in its main business[34]. Financial Position and Assets - The company's total assets at the end of the reporting period were ¥5,130,122,611.08, up 4.20% from the end of the previous year[23]. - The company's trading financial assets increased to ¥1,275,824,437.84, accounting for 24.87% of total assets, a 30.07% increase compared to the previous year[58]. - Accounts receivable notes rose significantly to ¥750,008,082.75, representing 14.62% of total assets, with a dramatic increase of 22,500.95% from the previous year[58]. - The company reported a total current assets of 3,484,116,530.22 RMB as of June 30, 2021, compared to 3,275,216,063.89 RMB at the end of 2020, indicating an increase[156]. - Total assets increased to ¥5,130,122,611.08, up from ¥4,923,573,835.05, representing a growth of approximately 4.22% year-over-year[161]. Cash Flow and Investment - The net cash flow from operating activities decreased significantly by 57.22%, amounting to ¥295,406,648.57[23]. - Cash flow from operating activities was CNY 295,406,648.57, down from CNY 690,545,105.25 in the first half of 2020, reflecting a decrease of approximately 57.3%[184]. - The net cash flow from investment activities was CNY -726,654,479.17, an improvement from CNY -970,899,071.37 in the first half of 2020[184]. - Cash inflow from investment activities increased significantly to CNY 1,590,774,528.64, up 196.5% from CNY 535,041,530.98 in the first half of 2020[188]. Environmental and Social Responsibility - The company has received the "Advanced Collective in Ecological Civilization Construction" honor from Jiangxi Provincial Government[97]. - The company has established comprehensive wastewater treatment facilities at both Jiangzhong Medicine Valley and Luoting bases[97]. - The company has implemented a gas boiler system using clean natural gas, achieving SO2 emissions close to zero and meeting the emission standards for nitrogen oxides[114]. - The company has successfully lifted all 49 residents of Nanzhou Village out of poverty through targeted assistance, improving public infrastructure and living conditions[123]. - The company has constructed 4.3 kilometers of new village roads and completed safety drinking water projects for 245 households in Nanzhou Village[125]. Corporate Governance and Shareholder Information - The company approved a restricted stock incentive plan on June 17, 2021, involving 6.3 million shares, accounting for 1.0% of the total share capital[93]. - The total number of common shareholders as of the end of the reporting period is 44,762[146]. - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, representing 43.03% of total shares[146]. - The company has committed to minimizing and regulating related party transactions with Jiangzhong Pharmaceutical, ensuring fair pricing and timely information disclosure[135]. - There are no significant lawsuits or arbitration matters during the reporting period[138].

证券代码：600750 证券简称：江中药业 公告编号：2021-019 江中药业股份有限公司 关于参加江西辖区上市公司 2021 年 投资者集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融 资计划、股权激励、可持续发展等投资者所关心的问题，江中药业股份有限公 司（以下简称"公司"）定于 2021 年 5 月 14 日下午 15:00—17:00 参加由江西 省上市公司协会联合深圳市全景网络有限公司举办的主题为"心系投资者 携手 高质量发展"江西上市公司 2021 年投资者集体接待日活动。现将有关事项公告 如下： 本次集体接待日网上交流网址：投资者可以登录 http://rs.p5w.net 进 入专区页面参与交流。 出席本次集体接待日的人员有：公司总经理蔡新平先生、财务总监李小俊 先生、董事会秘书田永静女士。 欢迎广大投资者积极参与。 特此公告。 江中药业股份有限公司董事会 2021 年 5 月 11 日 ...

[Part I. Important Notice](index=3&type=section&id=Part%20I.%20Important%20Notice) The company's Board of Directors, Supervisory Board, and senior management ensure the truthfulness, accuracy, and completeness of this quarterly report and assume corresponding legal responsibilities [1.1-1.4 Statement on Report Authenticity and Audit Status](index=3&type=section&id=1.1-1.4%20Statement%20on%20Report%20Authenticity%20and%20Audit%20Status) The company's Board of Directors, Supervisory Board, and senior management ensure the truthfulness, accuracy, and completeness of this quarterly report and assume corresponding legal responsibilities, with the report approved by all directors but unaudited - Company management guarantees the truthfulness, accuracy, and completeness of the quarterly report content and assumes legal responsibility[7](index=7&type=chunk)[8](index=8&type=chunk) - This company's Q1 2021 report is unaudited[9](index=9&type=chunk) [Part II. Company Profile](index=3&type=section&id=Part%20II.%20Company%20Profile) This section provides an overview of the company's key financial performance, operational highlights, and shareholder structure for the reporting period [2.1 Key Financial Data and Operating Performance](index=3&type=section&id=2.1%20Key%20Financial%20Data) In Q1 2021, the company achieved operating revenue of **RMB 677.47 million**, a 28.97% year-on-year increase, and net profit attributable to shareholders of **RMB 159.35 million**, up 21.25%, driven by traditional channel recovery and online expansion, with OTC drugs as a core revenue source and improved gross margin, despite a 59.23% year-on-year decline in net cash flow from operating activities Key Financial Indicators | Indicator | Q1 2021 | Q1 2020 | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 677,474,161.29 | 525,279,630.39 | 28.97% | | Net Profit Attributable to Parent Company Shareholders (RMB) | 159,348,929.61 | 131,424,924.09 | 21.25% | | Basic EPS (RMB/share) | 0.25 | 0.21 | 19.05% | | Net Cash Flow from Operating Activities (RMB) | 63,402,049.04 | 155,522,193.97 | -59.23% | - Operating revenue growth during the reporting period was primarily due to the gradual recovery of traditional channel demand and expansion of online channels as the pandemic improved[17](index=17&type=chunk) Main Business by Product | Main Business by Product | Operating Revenue (RMB) | Gross Margin (%) | Operating Revenue YoY Change (%) | Gross Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | | OTC Drugs | 560,369,687.62 | 67.96% | 25.73% | Increased by 2.64 percentage points | | Prescription Drugs | 67,223,736.83 | 58.98% | 16.45% | Decreased by 7.97 percentage points | | Health Products and Others | 48,535,054.30 | 44.13% | 131.27% | Decreased by 2.09 percentage points | - The increase in gross margin for OTC drugs was mainly due to a decrease in unit production costs resulting from increased output[17](index=17&type=chunk) [2.2 Total Shareholders, Top Ten Shareholders, and Top Ten Circulating Shareholders (or Unrestricted Shareholders) at Report End](index=5&type=section&id=2.2%20Total%20Shareholders%2C%20Top%20Ten%20Shareholders%2C%20and%20Top%20Ten%20Circulating%20Shareholders%20(or%20Unrestricted%20Shareholders)%20at%20Report%20End) As of the end of the reporting period, the company had **43,416 shareholders**, with China Resources Jiangzhong Pharmaceutical Group Co., Ltd. as the controlling shareholder holding **43.03%**, and no other related parties or concerted actions among the top ten shareholders - As of the end of the reporting period, the company had **43,416 shareholders**[18](index=18&type=chunk) Top Ten Shareholders | Shareholder Name | Shares Held (shares) | Proportion (%) | | :--- | :--- | :--- | | China Resources Jiangzhong Pharmaceutical Group Co., Ltd. | 271,071,486 | 43.03 | | Central Huijin Asset Management Co., Ltd. | 15,891,120 | 2.52 | | China Merchants Wealth Management - China Merchants Bank - China Merchants Wealth - Zhiyuan No. 2 Collective Asset Management Plan | 9,439,085 | 1.50 | [Part III. Significant Events](index=6&type=section&id=Part%20III.%20Significant%20Events) This section details significant financial and operational events, including major changes in financial items, progress on key matters, and performance forecasts [3.1 Significant Changes and Reasons for Key Accounting Statement Items and Financial Indicators](index=6&type=section&id=3.1%20Significant%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Statement%20Items%20and%20Financial%20Indicators) During the reporting period, several financial items experienced significant changes, with trading financial assets increasing by **30%** due to wealth management product purchases, while accounts receivable financing decreased by **95%** due to bill reclassification; sales and R&D expenses surged by **46%** and **120%** respectively to boost market and research efforts, and net cash flow from operating activities declined by **59%** due to reduced collection of matured bank acceptance bills - The period-end balance of trading financial assets increased by **30.09%** compared to the end of last year, primarily due to increased purchases of bank wealth management products using idle funds[21](index=21&type=chunk) - The period-end balance of accounts receivable financing decreased by **95.25%** compared to the end of last year, primarily due to bill reclassification[24](index=24&type=chunk) - Sales expenses increased by **46.18%** year-on-year, mainly due to increased marketing and promotion costs; R&D expenses increased by **119.87%** year-on-year, primarily due to an increase in R&D projects[24](index=24&type=chunk) - Net cash flow from operating activities decreased by **59.23%** year-on-year, primarily due to a decrease in the collection of matured bank acceptance bills[24](index=24&type=chunk) [3.2 Analysis of Progress, Impact, and Solutions for Significant Matters](index=7&type=section&id=3.2%20Analysis%20of%20Progress%2C%20Impact%2C%20and%20Solutions%20for%20Significant%20Matters) The company disclosed two significant matters: a **RMB 6.75 million** overdue entrusted loan is being pursued through communication and preparation for legal action, while the company actively utilized idle funds for entrusted wealth management, with **RMB 2.093 billion** invested at period-end, primarily in principal-protected floating-rate products [Entrusted Loan Status](index=7&type=section&id=Entrusted%20Loan%20Status) Of the **RMB 13.5 million** entrusted loan issued to Jiangxi Changrong Automobile Sales Co., Ltd. in 2018, **RMB 6.75 million** in principal remains overdue, with the company communicating with the borrower, guarantor, and insurer, and preparing for litigation if necessary to protect its rights - Of the entrusted loan to Changrong Automobile, **RMB 6.75 million** in principal is overdue[28](index=28&type=chunk) - The company is preparing to pursue recovery of the overdue loan through legal means[28](index=28&type=chunk) [Entrusted Wealth Management Status](index=9&type=section&id=Entrusted%20Wealth%20Management%20Status) As of the end of the reporting period, the company's total entrusted wealth management using its own funds amounted to **RMB 2.093 billion**, invested in structured deposits and wealth management products from multiple banks, primarily principal-protected and non-principal-protected floating-rate products, with realized gains of approximately **RMB 12.85 million** and expected gains of approximately **RMB 12.75 million** Entrusted Wealth Management Summary | Wealth Management Item | Amount (RMB) | | :--- | :--- | | Total Entrusted Wealth Management Amount | 2,093,000,000.00 | | Actual Period Gain | 12,853,257.30 | | Expected Gain | 12,751,912.34 | | Actual Principal Recovered | 823,000,000.00 | - The company plans to continue engaging in entrusted wealth management in the future[31](index=31&type=chunk)[34](index=34&type=chunk)[37](index=37&type=chunk) [3.4 Warning and Explanation of Potential Cumulative Net Profit Loss or Significant Change Compared to Prior Year-End to Next Reporting Period-End](index=14&type=section&id=3.4%20Warning%20and%20Explanation%20of%20Potential%20Cumulative%20Net%20Profit%20Loss%20or%20Significant%20Change%20Compared%20to%20Prior%20Year-End%20to%20Next%20Reporting%20Period-End) The company does not anticipate cumulative net profit from the beginning of the year to the end of the next reporting period to be a loss or to undergo significant changes compared to the same period last year - The company has not issued a warning regarding potential cumulative net profit loss or significant changes for the next reporting period[46](index=46&type=chunk) [Part IV. Appendix](index=15&type=section&id=Part%20IV.%20Appendix) This section contains the company's unaudited financial statements for the first quarter of 2021 and details on the first-time adoption of new lease standards [4.1 Financial Statements](index=15&type=section&id=4.1%20Financial%20Statements) This section provides the company's unaudited consolidated and parent company financial statements for Q1 2021, including the balance sheet, income statement, and cash flow statement, offering detailed data support for the report's financial analysis Consolidated Financial Statement Summary (March 31, 2021) | Consolidated Financial Statement Summary (March 31, 2021) | Amount (RMB) | | :--- | :--- | | **Balance Sheet** | | | Total Assets | 5,058,290,610.52 | | Total Liabilities | 644,863,526.22 | | Total Equity Attributable to Parent Company Shareholders | 4,036,223,213.00 | | **Income Statement (Q1 2021)** | | | Total Operating Revenue | 677,474,161.29 | | Total Profit | 190,218,880.73 | | Net Profit Attributable to Parent Company Shareholders | 159,348,929.61 | | **Cash Flow Statement (Q1 2021)** | | | Net Cash Flow from Operating Activities | 63,402,049.04 | | Net Cash Flow from Investing Activities | -54,024,668.41 | | Net Cash Flow from Financing Activities | 0.00 | [4.2 Adjustments to Financial Statements at the Beginning of the First Year of Adoption of New Lease Standards from 2021](index=27&type=section&id=4.2%20Adjustments%20to%20Financial%20Statements%20at%20the%20Beginning%20of%20the%20First%20Year%20of%20Adoption%20of%20New%20Lease%20Standards%20from%202021) Effective January 1, 2021, the company adopted new lease standards, retrospectively adjusting opening financial statements primarily by recognizing 'right-of-use assets' and 'lease liabilities' with minor adjustments to retained earnings, resulting in a limited impact on the overall asset and liability structure - The company first adopted new lease standards on January 1, 2021, and adjusted relevant items in the opening financial statements[88](index=88&type=chunk)[94](index=94&type=chunk) Key Consolidated Statement Adjustment Items | Key Consolidated Statement Adjustment Items | Adjustment Amount (RMB) | | :--- | :--- | | Right-of-Use Assets | +414,361.52 | | Lease Liabilities | +406,497.33 | | Retained Earnings | +6,315.28 | [4.4 Audit Report](index=32&type=section&id=4.4%20Audit%20Report) This quarterly financial report is unaudited - The audit report section of this quarterly report is marked 'Not Applicable,' indicating that the financial statements are unaudited[97](index=97&type=chunk)